Psychedelic News Roundup, July 2026: MDMA Therapy, Psilocybin Legalization, and Policy Shifts
July 2026 was a landmark month for psychedelic policy and research. MDMA-assisted therapy moved closer to FDA approval, two more states advanced psilocybin legalization, and a major study on psychedelic microdosing published unexpected results.
MDMA Therapy: Approaching the Finish Line
The biggest story of July 2026: the FDA accepted Lykos Therapeutics' revised MDMA therapy submission for priority review with a decision expected by Q4 2026. The new protocol addresses functional unblinding concerns with an active placebo.
Psilocybin: Massachusetts and New York Advance
Massachusetts Question 4 qualified for the November ballot to legalize psilocybin therapy. New York passed a $5 million research program. Total states with active psilocybin programs: 12.
Microdosing Study Surprises
A July 2026 RCT in Nature Mental Health found LSD microdosing (10 mcg) produced no cognitive improvement but significant mood benefits for mild depression.
Canada Expands Access
Health Canada's Special Access Program now covers psilocybin, MDMA, and LSD for a broader range of conditions. Requests up 340% since 2024 with zero serious adverse events.
Germany Legalizes Psychedelic Therapy
The German BfArM issued guidance allowing physicians to prescribe psilocybin and MDMA therapeutically under existing compassionate use regulations.
Sources: FDA, Nature Mental Health, Health Canada, BfArM.
Ready to Test Safely?
All reagents, test strips, and testing accessories mentioned in this guide are available in our catalog — shipped discreetly worldwide.